|
|
Office Locations:
|
1 Waukegan Road North
Chicago, IL 60064
Phone: 847-938-9400
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
AbbVie Ventures, Inc. is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, AbbVie Ventures characterizes an investment's success by its potential to significantly increase AbbVie's strategic growth, and not solely by its financial return. Companies with programs ranging from pre-clinical (18 months prior to first-in-human) to early proof-of-concept are of highest interest for potential investment. AbbVie Ventures invests in technologies that are strategic to AbbVie such as neuroscience, immunology, virology, and oncology, as well as emerging or more opportunistic areas of innovation that have the potential to complement AbbVie's existing portfolio or to expand AbbVie's future business reach. The initial investment can range from several hundred thousand dollars up to several million, depending on the opportunity and development stage. However, AbbVie Ventures will always remain a minority investor. AbbVie Ventures targets six to eight new investments annually.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
